BD ICU MEDICAL, INC., and B. Braun Medical Inc. are Expected to Dominate the Global Closed System Transfer Devices Market in 2021

Global Closed System Transfer Devices Market is expected to grow with the CAGR of 18.7% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @

Global closed system transfer devices market is highly fragmented, which includes a number of key players as well as local players. The market has witnessed increased strategic developments owing to favorable market scenario.

Major players operating in the global closed system transfer devices market are introducing a wide range of products. This helps companies to maximize their sales with enhance product portfolio.

For instance,

  • In October 2019, EQUASHIELD introduced its manual and automated CSTD solutions to the Netherlands through direct sales channels. This proactive approach by the company will facilitate health workers as they progress toward full compliance with safety recommendations. This will also help the company provide standard equipment’s for protecting healthcare workers handling hazardous drugs and also support sales across the region.


BD is the dominating player in the global closed system transfer devices market. Other key players operating in the market are B. Braun Medical Inc., ICU Medical, EQUASHIELD, Simplivia, Corvida Medical, YUKON MEDICAL, Caragen Ltd., Baxter, Vygon, and Epic Medical among others.

Global Closed System Transfer Devices Market BD

BD was founded in the year 1897 and it’s headquarter is located in the U.S. The Company is focused on providing superior healthcare services and facilities. Its product categories include anesthesia delivery, biopsy, diabetes care, cancer screening, hazardous drug safety, oncology and clinical care, and others. The company’s business segments are BD medical, BD interventional, and BD life science. The market focused category is hazardous drug safety.

  • In May 2021, BD announced its plan to build a USD 200.00 million high-tech manufacturing facility in Spain. It will also meet high sustainability and eco-efficiency standards, and will also be a fully digital site, incorporating latest intelligent and autonomous technologies, also known as industry 4.0 solutions. This will help the company produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs

The company offers services in over North America, Europe, Asia-Pacific, and Middle East & Africa regions.


ICU MEDICAL, INC. was founded in 1984 and is headquartered in the U.S. The company offers a wide range of IV therapy system and services to patients. Its product categories include infusion therapy, oncology, critical care, and IV solutions. The company has business segments including infusion consumables, infusion systems and solutions. The market focused segments is infusion consumables.

  • In February 2021, ICU Medical, Inc. received top-performing Smart Pump EMR-Integrated by KLAS Research for its Plum 360 smart infusion system. This award had served the company a recognition for the provider & payer organizations for infusion therapy and all critical care applications. With this, the company can advance its infusion system line and reduce medication errors, improve quality of care, streamline workflows, and maximize revenue capture.
  • In April 2019, ICU Medical, Inc. and Scripps Health signed an agreement stating the long-term purchase agreement covering ICU Medical’s full line of IV solutions and consumables along with the Plum 360 infusion system with ICU Medical MedNet IV medication safety software. With this, there is an increased level of clinical and IT diligence that Scripps Health performed to evaluate the technology and capabilities as part of its robust value analysis process. This will also help the company provide highest standard of patient care with advanced technology and solutions.

The company has presence across the globe in North America, Europe, and Asia-Pacific.


            B. BRAUN MEDICAL INC was founded in 1839 with its headquarter in the U.S. The company offers all advanced medical products. Its product categories include abdominal surgery, diabetes care, nutrition therapy, extracorporeal blood treatment, cardio-thoracic surgery, infection prevention, infusion therapy, interventional vascular therapy, continence care & urology, neurosurgery, sterile goods management, orthopaedic surgery, spine surgery, under which the market focused product is infusion therapy.

  • In March 2021, B. Braun Medical Inc. and Infraredx had announced that they will work together to expedite the FDA's Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent Please ReXTM Drug Coated PTCA Balloon Catheter, which had received FDA Certification in 2019.
  • In August 2020, B. Braun Medical Inc. had received clearance from the U.S. Food and Drug Administration (FDA) for Onvision, a breakthrough ultrasound guidance solution for real-time needle tip tracking. This had given the anesthesiologists the confidence to accurately position the needle tip inside the body for Peripheral Nerve Blocks (PNBs).

The company has presence in North America, Europe, Middle East and Africa, and Asia-Pacific.